Syndax Pharmaceuticals Stock EBITDA
| 1T3 Stock | EUR 13.50 0.40 3.05% |
Syndax Pharmaceuticals fundamentals help investors to digest information that contributes to Syndax Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Syndax Stock. The fundamental analysis module provides a way to measure Syndax Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Syndax Pharmaceuticals stock.
Syndax |
Syndax Pharmaceuticals Company EBITDA Analysis
Syndax Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Syndax Pharmaceuticals EBITDA | 26.22 M |
Most of Syndax Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Syndax Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Syndax Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of 26.22 M. This is 97.01% lower than that of the Healthcare sector and 73.82% lower than that of the Biotechnology industry. The ebitda for all Germany stocks is 99.33% higher than that of the company.
Syndax EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Syndax Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Syndax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics of similar companies.Syndax Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Syndax Fundamentals
| Return On Equity | -0.0519 | |||
| Return On Asset | -0.0292 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | (0.11) % | |||
| Current Valuation | 979.72 M | |||
| Shares Outstanding | 68.1 M | |||
| Shares Owned By Insiders | 4.22 % | |||
| Shares Owned By Institutions | 95.78 % | |||
| Price To Book | 4.08 X | |||
| Price To Sales | 12.70 X | |||
| Revenue | 139.71 M | |||
| Gross Profit | 139.71 M | |||
| EBITDA | 26.22 M | |||
| Net Income | 24.93 M | |||
| Cash And Equivalents | 95.37 M | |||
| Cash Per Share | 3.52 X | |||
| Total Debt | 19.89 M | |||
| Debt To Equity | 1.90 % | |||
| Current Ratio | 6.24 X | |||
| Book Value Per Share | 5.62 X | |||
| Cash Flow From Operations | 29.13 M | |||
| Target Price | 27.67 | |||
| Number Of Employees | 59 | |||
| Beta | 1.06 | |||
| Market Capitalization | 1.67 B | |||
| Total Asset | 449.66 M | |||
| Z Score | 49.8 | |||
| Net Asset | 449.66 M |
About Syndax Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Syndax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Syndax Stock
When determining whether Syndax Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Syndax Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Syndax Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Syndax Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.